SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael P. Michaud who wrote (117)3/15/1997 5:33:00 PM
From: Bharat H. Barai   of 834
 
Dear Mike,

I donot have Japanese market penetration data on Novastan. Heparin induced Thrombocytopenia occurs in appr. 3-6% people given Heparin, generally after 3-6 days of use. So it is possible that in ER you will not see Heparin induced Thrombocytopenia. This is well documented in literature for many years. In fact, continued use of Heparin in such patients can lead to wide spread Thromboembolism and death. At this time there is no good substitute, Argatroban will be first real substitute. Low Molecular wight heparin like Lovenox, used sbcut. for prophylaxis produce lower incidence of Heparin induced Thrombocytopenia but not eliminate it.

Novastan has much shorter half life, hence quick reversal of prolonged PTT and any bleeding complications. They have used it in open heart surgeries in almost 100 centers in USA during trials.

Bharat Barai MD
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News